Catalyst Pharmaceuticals - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים CPRX

Risks for Catalyst Pharmaceuticals (CPRX) are linked to excessive revenue concentration on a single product and patent disputes. Comparable year-over-year sales growth over 12 months visualizes the dynamics of these processes, where the 11.60 mark reflects the latest data. Development is based on the expansion of rare disease therapies, while operational efficiency is maintained through external GMP-standard manufacturing.
פילוחי נתונים אנליטיים מרוכזים עבור Catalyst Pharmaceuticals, Inc. (CPRX)

This indicator measures the daily revenue growth dynamics over a rolling year, allowing for an assessment of cash flow predictability. By analyzing year-over-year sales volatility over a rolling 12-month period, an investor can identify business stability or the risk of asset overvaluation. A stable trend here confirms the effectiveness of the monopoly pricing power of Catalyst Pharmaceuticals (CPRX). Inelastic demand for exclusive rare disease therapies provides the company with high fundamental resilience.